ArticleFrontiers in oncology2026
Postoperative recurrence and systemic metastasis of large cell neuroendocrine carcinoma of the breast: a case report including T-DXd treatment.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of large-cell neuroendocrine carcinoma (LCNEC) of the breast in a 49-year-old woman. The patient presented after discovering a right breast mass five years earlier. Mammography revealed a high-density mass and enlarged axillary lymph nodes. Biopsy confirmed invasive carcinoma with neuroendocrine differentiation. Initially, she received TE chemotherapy, followed by carboplatin and etoposide (CBP) due to disease progression. After eight cycles, she underwent modified radical mastectomy and postoperative radiotherapy. One year later, the patient developed metastases in the liver and bones, with a liver biopsy confirming recurrent LCNEC. Given the aggressive nature of the disease, trastuzumab deruxtecan (T-DXd) was initiated on October 11, 2025. Follow-up imaging demonstrated significant reduction in hepatic and peritoneal metastases, with partial response (PR) as the best observed response. Treatment with T-DXd is ongoing, highlighting its efficacy in managing aggressive LCNEC with distant metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.